Cochrane · systematic review · CD013836
Antibiotic regimens for late‐onset neonatal sepsis
Korang, SK, Safi, S, Nava, C, et al. · Cochrane Database of Systematic Reviews · 2021 · Cochrane Library
NeonatalAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
15
current version
GRADE rated
15
No studies
0
Included studies
NR
No studies 0 · 0%Ungraded 0 · 0%Very low 15 · 100%Low 0 · 0%Moderate 0 · 0%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Cefazolin plus amikacin compared with vancomycin plus amikacin for late‐onset neonatal sepsis
Population: newborns with late‐onset sepsis
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
All‐cause mortality maximum Cefazolin plus amikacin vs vancomycin plus amikacin | RR 0.7 [0.29, 1.66] | 1 study · 109 participants | Very low Downgraded: risk of bias, imprecision, indirectness |
Serious adverse events maximum Cefazolin plus amikacin vs vancomycin plus amikacin | RR 0.7 [0.29, 1.66] | 1 study · 109 participants | Very low Downgraded: risk of bias, imprecision, indirectness |
Ticarcillin plus clavulanic acid compared with flucloxacillin and gentamicin for late‐onset neonatal sepsis
Population: newborns with late‐onset sepsis
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
All‐cause mortality maximum Ticarcillin plus clavulanic acid vs flucloxacillin and gentamicin | RR 0.2 [0.01, 3.82] | 1 study · 28 participants | Very low Downgraded: risk of bias, imprecision, indirectness |
Serious adverse events maximum Ticarcillin plus clavulanic acid vs flucloxacillin and gentamicin | RR 0.2 [0.01, 3.82] | 1 study · 28 participants | Very low Downgraded: risk of bias, imprecision, indirectness |
Cloxacillin plus amikacin compared with cefotaxime plus gentamicin for neonatal late‐onset sepsis
Population: newborns with late‐onset sepsis
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
All‐cause mortality maximum Cloxacillin plus amikacin vs cefotaxime plus gentamicin | RR 0.38 [0.11, 1.27] | 1 study · 90 participants | Very low Downgraded: risk of bias, imprecision, indirectness |
Serious adverse events maximum Cloxacillin plus amikacin vs cefotaxime plus gentamicin | RR 0.5 [0.17, 1.48] | 1 study · 90 participants | Very low Downgraded: risk of bias, imprecision, indirectness |
Circulatory support maximum Cloxacillin plus amikacin vs cefotaxime plus gentamicin | RR 0.5 [0.17, 1.48] | 1 study · 90 participants | Very low Downgraded: risk of bias, imprecision, indirectness |
Nephrotoxicity maximum Cloxacillin plus amikacin vs cefotaxime plus gentamicin | RR 0.25 [0.03, 2.05] | 1 study · 90 participants | Very low Downgraded: risk of bias, imprecision, indirectness |
Meropenem compared with standard care for neonatal late‐onset sepsis
Population: newborns with late‐onset sepsis
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
All‐cause mortality maximum Meropenem vs standard care | RR 1.42 [0.56, 3.62] | 1 study · 271 participants | Very low Downgraded: risk of bias, imprecision, indirectness |
Serious adverse events maximum Meropenem vs standard care | RR 1.54 [0.9, 2.66] | 1 study · 271 participants | Very low Downgraded: risk of bias, imprecision, indirectness |
Neurological developmental impairment maximum Meropenem vs standard care | RR 0.87 [0.51, 1.48] | 1 study · 271 participants | Very low Downgraded: risk of bias, imprecision, indirectness |
Necrotising enterocolitis maximum Meropenem vs standard care | RR 0.68 [0.33, 1.42] | 1 study · 271 participants | Very low Downgraded: risk of bias, imprecision, indirectness |
Vancomycin plus gentamicin compared with vancomycin plus aztreonam for late‐onset neonatal sepsis
Population: newborns with late‐onset sepsis
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
All‐cause mortality maximum Vancomycin plus gentamicin vs vancomycin plus aztreonam | RR 0.65 [0.2, 2.13] | 1 study · 81 participants | Very low Downgraded: risk of bias, imprecision, indirectness |
Serious adverse events maximum Vancomycin plus gentamicin vs vancomycin plus aztreonam | RR 0.65 [0.2, 2.13] | 1 study · 81 participants | Very low Downgraded: risk of bias, imprecision, indirectness |
Necrotising enterocolitis maximum Vancomycin plus gentamicin vs vancomycin plus aztreonam | RR 12.69 [0.74, 218.09] | 1 study · 81 participants | Very low Downgraded: risk of bias, imprecision, indirectness |